Global pharmaceutical leader Eli Lilly and Company today announced a $500 million investment over the next five years to advance South Korea’s pharmaceutical and biotechnology ecosystem. The initiative aims to support biotech startups, expand research collaborations, and attract global clinical trials to the country.

The commitment was formalized through a memorandum of understanding signed with the South Korean Ministry of Health and Welfare, highlighting a shared vision to accelerate innovative drug development and enhance the global competitiveness of domestic biotech firms.

“This agreement will serve as a meaningful opportunity to strengthen the innovation capacity of Korea’s pharmaceutical and biopharma industry while accelerating drug development by promising domestic companies,” said Minister Jeong Eun-kyeong, South Korea’s Minister of Health and Welfare.

A cornerstone of the investment is the expansion of Lilly Gateway Labs, the company’s global innovation program launched in 2019 to support early-stage biotech startups. The South Korean hub will be established in collaboration with Samsung Biologics at its Second Bio Campus in Songdo, Incheon. Located within the forthcoming C-Lab Outside open innovation center, the facility is expected to open in 2027 and accommodate up to 30 biotech companies, providing access to laboratory space, industry expertise, and global partnerships.

“Lilly Gateway Labs is designed to bridge the gap between early scientific discovery and global drug development,” said a company spokesperson. “By nurturing startups in South Korea, we aim to accelerate the path from innovation to real-world therapies.”

This announcement follows similar commitments from global biopharma leaders, including Roche, which pledged $480 million to South Korea’s industry over the next five years. These investments collectively underscore the country’s emergence as a leading life sciences hub in Asia, driven by advanced hospitals, skilled researchers, supportive regulations, and strong manufacturing capabilities.

South Korea’s growing biotech ecosystem positions the nation at the forefront of innovations in longevity, metabolic treatments, and gene-based medicines. By combining local expertise with global partnerships, Lilly’s investment aims to foster an environment where cutting-edge discoveries can rapidly advance to clinical application.